MedPath

Effectiveness and Cost-effectiveness of the Initial Medication Adherence Intervention

Not Applicable
Active, not recruiting
Conditions
Adherence, Medication
Interventions
Other: Usual care
Behavioral: Initial Medication Adherence (IMA)
Registration Number
NCT05026775
Lead Sponsor
Fundació Sant Joan de Déu
Brief Summary

The purpose of this study is to assess the effectiveness and the cost-effectiveness of the Initial Medication Adherence (IMA) Intervention.

Detailed Description

A pragmatic cluster randomised control trial will be conducted to evaluate the effectiveness of the IMA intervention in comparison to usual care, in the increase of initiation of medicines for CVD and diabetes (antihypertensive, lipid-lowering, antidiabetic and antiplatelet medications) prescribed in Primary Care (PC). The impact of the IMA intervention on secondary adherence and clinical indicators will be evaluated.

A multicenter pragmatic RCT, with cluster allocation and 2 parallel branches (IMA intervention vs. usual care) based on health records or RWD will be conducted.

PC centres' personnel, including general practitioners (GP), nurses and community pharmacists, from different areas around Catalonia (Spain), will be cluster randomised 1:1 into intervention and control groups, stratified according to the type of PC centre, either rural or urban and taking into consideration the size and localization of the PC centre and the main predictors of non-initiation (socioeconomic status, mean age, % immigrant population of the PC centre).

The IMA intervention will provide clinicians with knowledge, skills and tools to help the patient make an informed decision. PC centre personnel in the intervention group will receive training on medication non-initiation, communication abilities, health literacy, shared decision making and the use of support tools such as leaflets and the IMA website.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
4153
Inclusion Criteria
  • Primary Care health professionals and pharmacists who:
  • Agree to participate in the clinical trial and process evaluation.
  • Attend the training course
  • Are not plannig to be on sick leave during the study period (e.g. maternity leave).
  • Patients who:
  • Are prescribed a new treatment of cardiovascular disease o diabetes by a doctor who participates in the clinical trial.
  • Are >18 years old
  • Do not reject to participate
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Usual careUsual carePatients will receive the usual care when being prescribed a new prescription for treatment of cardiovascular disease or diabetes. Nurses and community pharmacists will be asked to also provide usual care to those patients.
Initial Medication Adherence (IMA) interventionInitial Medication Adherence (IMA)General practitioners (GP) will apply the IMA intervention to all patients receiving a new prescription for treatment of cardiovascular disease or diabetes. Following the IMA intervention, nurses and community pharmacists will offer information support in line with the information provided by the GP.
Primary Outcome Measures
NameTimeMethod
Rate of Initiation1 month and 3 months after recruitment

Patients who receive a new prescription (a prescription is considered new if there is no previouos prescription from the same group in the previous 6 months) will be considered initiators if they fill-up their prescription in the community pharmacy.

Prescription and dispensation databases will be compared to classify prescriptions as initiated and non-initiated.

Secondary Outcome Measures
NameTimeMethod
Reduction of Cardiovascular Risk1 year after recruitment

Framingham risk score will be calculated.

Rate of adherence1 year after recruitment

Adherence will be calculated based on the Medication Possesion Ratio (MPR is the sum of the days' supply for all fills of a given drug in a particular time period, divided by the number of days in the time period).

Trial Locations

Locations (24)

CAP Calaf

🇪🇸

Calaf, Barcelona, Spain

CAP Pou Torre

🇪🇸

Begues, Barcelona, Spain

CAP Corbera de Llobregat

🇪🇸

Corbera De Llobregat, Barcelona, Spain

CAP La Llagosta

🇪🇸

La Llagosta, Barcelona, Spain

CAP Montornès del Vallès

🇪🇸

Montornès Del Vallès, Barcelona, Spain

CAP Ripollet

🇪🇸

Ripollet, Barcelona, Spain

Parc Sanitari Sant Joan de Déu

🇪🇸

Sant Boi De Llobregat, Barcelona, Spain

CAP Vinyets

🇪🇸

Sant Boi De Llobregat, Barcelona, Spain

CAP Sant Sadurni d'Anoia

🇪🇸

Sant Sadurní d'Anoia, Barcelona, Spain

CAP Sant Vicenç de Castellet

🇪🇸

Sant Vicenç de Castellet, Barcelona, Spain

CAP Sitges

🇪🇸

Sitges, Barcelona, Spain

CAP Montcada i Reixac

🇪🇸

Montcada i Reixac, Barcelon, Spain

CAP de Tremp

🇪🇸

Tremp, Lleida, Spain

CAP Sort

🇪🇸

Sort, Lleida, Spain

CAP Cornudella de Montsant

🇪🇸

Cornudella de Montsant, Tarragona, Spain

CAP Sant Pere

🇪🇸

Reus, Tarragona, Spain

CAP Santa Coloma de Queralt

🇪🇸

Santa Coloma De Queralt, Tarragona, Spain

CAP Drassanes

🇪🇸

Barcelona, Spain

CAP Horta

🇪🇸

Barcelona, Spain

CAP La Marina

🇪🇸

Barcelona, Spain

CAP Bonavista

🇪🇸

Tarragona, Spain

CAP Montilivi

🇪🇸

Girona, Spain

CAP Sant Pere i Sant Pau

🇪🇸

Tarragona, Spain

CAP Martorell

🇪🇸

Martorell, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath